Stock Price & Analysis

The price target for BIIB stock in 2025 is approximately $197.55, based on analyst consensus, representing a 38% upside from current levels. This prediction is supported by Biogen's potential execution on its pipeline and business development initiatives, despite expectations of a mid-single-digit revenue decline in 2025. The stock's current price of $141.61 reflects a balance between its challenging legacy portfolio and optimism around new launches.

The S1 support level for BIIB Stock is $138.83 ,The R1 resistant level for BIIB Stock is $144.77.

As of the end of day on 2025-03-31, the price of BIIB Stock was $136.73.

The target price for BIIB Stock according to analyst rating is 192.43, with the highest price target at 265.00 and the lowest at 135.00. Analysts have a Moderate Buy rating on BIIB Stock overall.

The market cap of BIIB is $20.3B.

Analysis and Insights

Valuation Metrics:

Biogen Inc. (BIIB) currently exhibits elevated valuation metrics compared to industry peers. The price-to-earnings (P/E) ratio ranges between 26.96 and 13.67, which is higher than the biotechnology sector average. The EV/EBITDA ratio of 13.37 to 8.06 suggests moderate valuation, while the price-to-sales (P/S) ratio of 3.25 to 2.31 indicates a premium. The price-to-book (P/B) ratio of 2.06 to 1.33 is slightly above average, signaling potential overvaluation.

Financial Performance:

BIIB's total revenue has shown steady growth, reaching $2.4547 billion in Q4 2024. However, net income has fluctuated, with Q4 2024 net income at $266.7 million, down from $583.6 million in Q2. Gross margin remains robust at 68.81% to 74.32%, but return on equity (ROE) has declined, indicating profitability challenges.

Market Trends and Competition:

BIIB's stock has underperformed the broader market and competitors like Gilead Sciences (GILD). The stock is trading below its 200-day moving average, signaling a bearish trend. Additionally, challenges such as declining UK investment due to high levies and competitive pressures from Novartis's gene therapy for SMA pose risks to BIIB's market share.

Analyst Sentiment and Projections:

Analysts maintain a "Moderate Buy" rating with a mean price target of $197.55, suggesting a 38.1% upside. However, BIIB projects a mid-single-digit revenue decline for 2025, with adjusted EPS expected between $15.25 and $16.25, below 2024's $16.47.

Conclusion:

Considering the high valuation metrics, fluctuating profitability, competitive pressures, and market underperformance, BIIB appears overvalued at current levels. Investors should exercise caution and consider waiting for a price correction or improved fundamentals before investing.

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Price Prediction for BIIB Stock in 2030

Based on current trends and analyst projections, BIIB stock is expected to reach $250-$300 by 2030. This prediction is supported by the company's strong pipeline, including Leqembi and Skyclarys, which are anticipated to drive future growth and offset declines in its multiple sclerosis portfolio.

BIIB has a total of 7570 employees.